|
CN103168037A
|
|
Synthesis and use of kinase inhibitors
|
|
CN103313697A
|
|
Oral formulation of kinase inhibitors
|
|
KR20130085939A
|
|
Method to treat small cell lung cancer
|
|
EP2464642A1
|
|
Method of promoting apoptosis and inhibiting metastasis
|
|
KR20120037377A
|
|
Improved synthesis of picoplatin
|
|
US2010260832A1
|
|
Combination therapy for ovarian cancer
|
|
WO2010132594A1
|
|
Use of picoplatin to treat prostate cancer
|
|
WO2010132596A1
|
|
Use of picoplatin to treat colorectal cancer
|
|
WO2010120336A1
|
|
High bioavailability oral picoplatin anti-cancer therapy
|
|
US2011033528A1
|
|
Stabilized picoplatin oral dosage form
|
|
EP2273882A1
|
|
Bioactive compounds for treatment of cancer and neurodegenerative diseases
|
|
US2011098241A1
|
|
Rapamycin analogs as anti-cancer agents
|
|
AU2009210654A1
|
|
Use of picoplatin and bevacizumab to treat colorectal cancer
|
|
WO2009011861A1
|
|
Oral formulations for picoplatin
|
|
TW200916094A
|
|
Stabilized picoplatin dosage form
|
|
EP2114418A1
|
|
Stabilized picoplatin oral dosage form
|
|
EP2109451A1
|
|
Encapsulated picoplatin
|
|
UA100508C2
|
|
Encapsulated picoplatin for oral administration
|
|
EP0909277A2
|
|
Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods
|
|
EP1980246A1
|
|
Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
|
